STRO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
9.1M
-7.5%
9.8M
-32.3%
14.5M
+24.7%
11.6M
+20.2%
9.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.1M
-7.5%
9.8M
-32.3%
14.5M
+24.7%
11.6M
+20.2%
9.7M
Operating Expenses
31.1M
-21.8%
39.7M
-10.1%
44.2M
-11.1%
49.7M
-14.5%
58.2M
R&D
23.5M
-25.9%
31.7M
-13.3%
36.6M
-0.2%
36.6M
-8.1%
39.9M
SG&A
7.5M
-3.7%
7.8M
+3.3%
7.6M
-12.4%
8.7M
-0.9%
8.7M
Operating Income
-21956000
+26.5%
-29888000
-0.8%
-29656000
+22.1%
-38049000
+21.5%
-48459000
EBITDA
-20696000
+27.2%
-28425000
-0.3%
-28336000
+11.5%
-32033000
+13.4%
-37001000
Net Income
-31489000
+18.3%
-38533000
-0.1%
-38484000
+17.7%
-46762000
+17.8%
-56857000
EPS (Basic)
$-1.90
+18.5%
$-2.33
+20.7%
$-2.94
+46.1%
$-5.45
+18.2%
$-6.66
EPS (Diluted)
$-1.90
+18.5%
$-2.33
+20.7%
$-2.94
+46.1%
$-5.45
+18.2%
$-6.66
Shares (Diluted)
16.6M
+0.1%
16.6M
+26.7%
13.1M
+52.6%
8.6M
+0.4%
8.5M
Sutro Biopharma (STRO) — Financials